Perspective Therapeutics (CATX) EBITDA Margin Growth (3y) (2013 - 2023)
Perspective Therapeutics (CATX) EBITDA Margin Growth (3y) (2013 - 2023) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | -343.00 |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 17.00 |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 78.00 |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 487.00 |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | -283.00 |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 1,505.00 |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | -763.00 |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | -184.00 |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Perspective Therapeutics | 146.05 Mn | 146.05 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 27,520.00 |
| Sep 30, 2023 | -41,627.00 |
| Jun 30, 2023 | -59,809.00 |
| Mar 31, 2023 | -45,412.00 |
| Sep 30, 2022 | -7,171.00 |
| Jun 30, 2022 | -484.00 |
| Mar 31, 2022 | 1,316.00 |
| Dec 31, 2021 | 1,699.00 |
| Sep 30, 2021 | 849.00 |
| Jun 30, 2021 | 19,752.00 |
| Mar 31, 2021 | 5,566.00 |
| Dec 31, 2020 | 5,857.00 |
| Sep 30, 2020 | 9,821.00 |
| Jun 30, 2020 | 8,389.00 |
| Mar 31, 2020 | 8,932.00 |
| Dec 31, 2019 | 10,294.00 |
| Sep 30, 2019 | 10,959.00 |
| Jun 30, 2019 | 5,250.00 |
| Mar 31, 2019 | 5,032.00 |
| Dec 31, 2018 | 4,353.00 |